- 1、本文档共28页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
* Bev, bevacizumab; FOLFIRI, irinotecan, 5-fluorouracil, leucovorin; FOLFOXIRI, 5-fluorouracil, leucovorin, oxaliplatin, irinotecan; mCRC, metastatic colorectal cancer; OS, overall survival; PFS, progression-free survival. Results from the TRIBE study, with a median follow-up of 48 months, showed a statistically significant improvement in median OS of approximately 4 months, favoring the triple-drug combination.[4] In my opinion, this is a clinically significant improvement. The PFS was similarly improved, with an HR of 0.77. ? However, it is not clear whether all patients with CRC can tolerate triple-drug therapy, which may be most appropriate for only a subset of patients. This should be the subject of future studies before this regimen becomes the standard of care. For example, if response is an important endpoint for a particular individual who may be having some discomfort or is at risk of having organ function threatened by bulky disease, it would be reasonable to go with the more aggressive therapy first. ? In my practice, when I do choose a triple-drug combination, which is not very often, once a response is achieved, I will taper down to 2 drugs by stopping the most toxic of the 3 agents. This varies depending on the patient, who may have more trouble with irinotecan or oxaliplatin adverse events. * * FOLFIRI, irinotecan, 5-fluorouracil, leucovorin; IV, intravenous; mCRC, metastatic colorectal cancer; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression free survival.; q2w, every 2 weeks. RAISE is a phase III trial designed to answer an important question: Is there value to ramucirumab as second?line therapy if combined with FOLFIRI in patients with metastatic CRC who fail first?line chemotherapy with an oxaliplatin- and bevacizumab?containing regimen? In this well-designed trial, patients (N = 1050) were randomized to receive either FOLFIRI alone at standard doses or FOLFIRI plus ramucirumab at 8?mg/kg every
您可能关注的文档
最近下载
- 对照《中国共产党纪律处分条例》排查梳理违纪风险点(共30条,包含产生因素和防范举措).docx VIP
- 初中物理教师招聘选调考试精彩试题.docx
- 房屋租赁合同70582.doc
- 初中物理探究式教学研究结题报告草稿.doc
- 培训机构辅导班兼职教师聘用合同协议.doc
- 2022-2023学年北京市西城区高二下学期期末考试语文试题(解析版).docx
- 舞剧的僭越——作为符号的舞蹈诗剧《只此青绿》.pdf VIP
- DB53/T 2007-2015- 钢筋保护层混凝土垫块质量检测技术规程.pdf
- 初中物理教师招聘选调考试试题(2).doc VIP
- 学前儿童社会教育(学前儿童社会教育活动指导)-国家开放大学电大期末纸考卷考题目答案.pdf
文档评论(0)